With its concise outline format, abundant illustrations, and features that promote high-yield study and effective retention, Nephrology and Hypertension Board Review + Practice Test is the “go-to” book for those seeking certification and recertification in nephrology with the American Board of Internal Medicine or just mastering the knowledge required in the daily practice of nephrology and hypertension. Edited by Drs. Phuong-Chi T. Pham and Phuong-Thu T. Pham, the fully revised 3rd Edition proportionally covers all topics listed in the updated blueprint for the exam, offers ample opportunity for practice, and helps with identifying areas for further study.
1. Cover - p. Cover 2. Title Page - p. iii 3. Copyright - p. iv 4. Contributing Authors - p. v 5. Preface - p. vii 6. Abbreviations - p. ix 7. Acknowledgments - p. xix 8. Contents - p. xxi 9. 1 Sodium and Water Abnormalities - p. 1 10. HYPONATREMIA - p. 1 11. FLUID MANAGEMENT - p. 16 12. HYPERNATREMIA AND HYPEROSMOLALITY - p. 19 13. SALT EXCESS - p. 25 14. SALT DEPLETION - p. 39 15. POLYURIA - p. 47 16. 2 Acid-Base and Potassium Disorders - p. 57 17. ACID-BASE DISORDERS - p. 57 18. METABOLIC ACIDOSIS, ELEVATED SERUM ANION GAP (SAG) - p. 61 19. METABOLIC ACIDOSIS, NORMAL SAG - p. 70 20. METABOLIC ALKALOSIS - p. 79 21. RESPIRATORY ALKALOSIS - p. 85 22. RESPIRATORY ACIDOSIS - p. 85 23. POTASSIUM - p. 85 24. HYPERKALEMIA - p. 90 25. HYPOKALEMIA - p. 98 26. 3 Calcium, Phosphorus, and Magnesium Disorders, and Kidney Stones - p. 113 27. DISORDERS OF CALCIUM METABOLISM - p. 113 28. HYPERCALCEMIA - p. 121 29. HYPOCALCEMIA - p. 127 30. DISORDERS OF PHOSPHATE METABOLISM - p. 130 31. HYPERPHOSPHATEMIA - p. 133 32. HYPOPHOSPHATEMIA - p. 136 33. SECONDARY HYPERPARATHYROIDISM - p. 139 34. DISORDERS OF MAGNESIUM METABOLISM - p. 148 35. HYPOMAGNESEMIA - p. 151 36. HYPERMAGNESEMIA - p. 157 37. KIDNEY STONES - p. 158 38. 4 Chronic Kidney Disease - p. 175 39. ASSESSMENT OF CHRONIC KIDNEY DISEASE (CKD) - p. 175 40. RISK ASSESSMENT OF CKD (KDIGO 2024) - p. 183 41. SLOWING CKD PROGRESSION AND MANAGING CV COMPLICATIONS - p. 185 42. MANAGING CKD COMPLICATIONS - p. 195 43. STAGES IV AND V CKD - p. 214 44. END-STAGE KIDNEY DISEASE (ESKD) - p. 217 45. SPECIAL TOPICS IN CKD - p. 248 46. 5 Hypertension - p. 255 47. HYPERTENSION BACKGROUND AND DEFINITIONS - p. 255 48. EVALUATION OF HTN - p. 262 49. SECONDARY CAUSES OF HTN - p. 263 50. END-ORGAN DAMAGE OF HTN - p. 283 51. PHARMACOLOGIC THERAPY FOR HTN - p. 285 52. HYPERTENSIVE EMERGENCIES - p. 288 53. PREGNANCY AND HTN - p. 293 54. 6 Tubular, Interstitial, and Cystic Disorders - p. 301 55. RENAL TUBULAR DISORDERS AND FANCONI SYNDROME - p. 301 56. INTERSTITIAL/TUBULOINTERSTITIAL NEPHRITIS - p. 304 57. CHRONIC INTERSTITIAL NEPHRITIS - p. 311 58. RENAL CYSTIC DISEASES - p. 322 59. POLYCYSTIC KIDNEY DISEASES (PKDs) - p. 328 60. 7 Glomerular and Vascular Disorders - p. 349 61. GENERAL MANAGEMENT CONSIDERATIONS FOR GLOMERULAR/VASCULAR DISEASES (KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES [KDIGO] 2021) - p. 349 62. NEPHRITIC GLOMERULAR DISORDERS AND VASCULITIS/VASCULOPATHY - p. 354 63. RENAL AND SYSTEMIC VASCULITIDES - p. 360 64. LUPUS NEPHRITIS (LN) - p. 371 65. ANTI-GBM DISEASE (GOODPASTURE SYNDROME) - p. 379 66. GLOMERULAR INJURY ASSOCIATED WITH INFECTIONS - p. 382 67. NEPHROTIC/HEAVY PROTEINURIC GLOMERULAR DISORDERS - p. 391 68. PARAPROTEIN-RELATED DISORDERS - p. 406 69. ALPORT SYNDROME - p. 415 70. THROMBOTIC MICROANGIOPATHY / HEMOLYTIC-UREMIC SYNDROME - p. 420 71. DIABETIC KIDNEY DISEASE (DKD) - p. 430 72. SICKLE CELL DISEASE (SCD) - p. 436 73. VIRAL NEPHRITIDES - p. 441 74. FABRY DISEASE - p. 446 75. SCLERODERMA AND THE KIDNEYS - p. 448 76. 8 Transplant Immunobiology - p. 449 77. BACKGROUND - p. 449 78. HLA-TYPING TECHNIQUES - p. 453 79. MINOR HISTOCOMPATIBILITY ANTIGENS - p. 454 80. NON-HUMAN LEUKOCYTE ANTIGENS - p. 455 81. ALLORECOGNITION PATHWAYS: DIRECT, INDIRECT, AND SEMIDIRECT ALLORECOGNITION - p. 456 82. HLA ALLOSENSITIZATION - p. 457 83. TECHNIQUES FOR DETECTION OF ANTI-HLA ANTIBODIES: GENERAL CONCEPT - p. 457 84. DETERMINATION OF HLA SENSITIZATION - p. 458 85. VIRTUAL CROSSMATCH - p. 462 86. PHYSICAL CROSSMATCH - p. 463 87. IMMUNOLOGIC EVALUATION OF THE TRANSPLANT CANDIDATE - p. 465 88. 9 Kidney Transplantation - p. 467 89. EVALUATION OF THE POTENTIAL KIDNEY TRANSPLANT CANDIDATE - p. 467 90. LIVING DONOR EVALUATION - p. 473 91. KIDNEY ALLOCATION SYSTEM - p. 480 92. IMMUNOSUPPRESSIVE AGENTS - p. 482 93. ALLOGRAFT REJECTION: TYPES AND TREATMENT STRATEGIES - p. 491 94. KIDNEY ALLOGRAFT BIOPSY - p. 495 95. NONINVASIVE BIOMARKERS FOR EARLY DETECTION OF GRAFT INJURY AND REJECTION - p. 505 96. POSTTRANSPLANTATION INFECTIOUS COMPLICATIONS AND VACCINATIONS - p. 506 97. NONINFECTIOUS COMPLICATIONS AFTER KIDNEY TRANSPLANT - p. 521 98. POSTTRANSPLANTATION BONE AND MINERAL DISORDER - p. 534 99. POSTTRANSPLANTATION MALIGNANCY - p. 539 100. MALE AND FEMALE FERTILITY - p. 544 101. MULTIORGAN TRANSPLANTATION - p. 545 102. 10 Pharmacology - p. 549 103. PHARMACOKINETICS - p. 549 104. DRUG SELECTION AND DOSE ADJUSTMENT IN KIDNEY DISEASE - p. 554 105. NEPHROTOXICITY OF MEDICATIONS - p. 564 106. NEPHROTOXICITY OF ENVIRONMENTAL AND OCCUPATIONAL AGENTS - p. 572 107. SPECIFIC DRUG ADVERSE EFFECTS OF INTEREST TO THE NEPHROLOGIST - p. 573 108. IMMUNOSUPPRESSIVE THERAPY (see also Chapter 9: Kidney Transplantation) - p. 575 109. ANTICOAGULANTS, ANTIPLATELETS, THROMBOLYTICS, AND HEMOSTATICS - p. 577 110. DRUG INTERACTION/ADVERSE EFFECTS (OTHER THAN NEPHROTOXICITY) - p. 581 111. CORONAVIRUS DISEASE 2019 (COVID-19) DRUG THERAPY AND DRUG-DRUG INTERACTION/ADVERSE EFFECTS - p. 582 112. DIALYSIS AND OTHER TREATMENT OF POISONINGS - p. 583 113. COMMON POISONINGS THAT MAY REQUIRE EXTRACORPOREAL REMOVAL - p. 584 114. 11 Acute Kidney Injury/Intensive Care Unit (ICU) Nephrology - p. 589 115. ACUTE KIDNEY INJURY (AKI) - p. 589 116. ICU NEPHROLOGY - p. 619 117. HEMODYNAMIC MONITORING - p. 626 118. 12 Continuous Kidney Replacement Therapy - p. 631 119. BACKGROUND - p. 631 120. Appendix A: Facts, Formulas, and Protocols Beyond the ABIM Board Exam - p. 639 121. Appendix B: Supplemental Study Materials on Acid-Base Disorders - p. 677 122. Appendix C: Suggested Readings - p. 685 123. Practice Test - p. 698 124. Index - p. 699
No hay muestra disponible
No hay ficha técnica disponible
With its concise outline format, abundant illustrations, and features that promote high-yield study and effective retention, Nephrology and Hypertension Board Review + Practice Test is the “go-to” book for those seeking certification and recertification in nephrology with the American Board of Internal Medicine or just mastering the knowledge required in the daily practice of nephrology and hypertension. Edited by Drs. Phuong-Chi T. Pham and Phuong-Thu T. Pham, the fully revised 3rd Edition proportionally covers all topics listed in the updated blueprint for the exam, offers ample opportunity for practice, and helps with identifying areas for further study.
1. Cover - p. Cover 2. Title Page - p. iii 3. Copyright - p. iv 4. Contributing Authors - p. v 5. Preface - p. vii 6. Abbreviations - p. ix 7. Acknowledgments - p. xix 8. Contents - p. xxi 9. 1 Sodium and Water Abnormalities - p. 1 10. HYPONATREMIA - p. 1 11. FLUID MANAGEMENT - p. 16 12. HYPERNATREMIA AND HYPEROSMOLALITY - p. 19 13. SALT EXCESS - p. 25 14. SALT DEPLETION - p. 39 15. POLYURIA - p. 47 16. 2 Acid-Base and Potassium Disorders - p. 57 17. ACID-BASE DISORDERS - p. 57 18. METABOLIC ACIDOSIS, ELEVATED SERUM ANION GAP (SAG) - p. 61 19. METABOLIC ACIDOSIS, NORMAL SAG - p. 70 20. METABOLIC ALKALOSIS - p. 79 21. RESPIRATORY ALKALOSIS - p. 85 22. RESPIRATORY ACIDOSIS - p. 85 23. POTASSIUM - p. 85 24. HYPERKALEMIA - p. 90 25. HYPOKALEMIA - p. 98 26. 3 Calcium, Phosphorus, and Magnesium Disorders, and Kidney Stones - p. 113 27. DISORDERS OF CALCIUM METABOLISM - p. 113 28. HYPERCALCEMIA - p. 121 29. HYPOCALCEMIA - p. 127 30. DISORDERS OF PHOSPHATE METABOLISM - p. 130 31. HYPERPHOSPHATEMIA - p. 133 32. HYPOPHOSPHATEMIA - p. 136 33. SECONDARY HYPERPARATHYROIDISM - p. 139 34. DISORDERS OF MAGNESIUM METABOLISM - p. 148 35. HYPOMAGNESEMIA - p. 151 36. HYPERMAGNESEMIA - p. 157 37. KIDNEY STONES - p. 158 38. 4 Chronic Kidney Disease - p. 175 39. ASSESSMENT OF CHRONIC KIDNEY DISEASE (CKD) - p. 175 40. RISK ASSESSMENT OF CKD (KDIGO 2024) - p. 183 41. SLOWING CKD PROGRESSION AND MANAGING CV COMPLICATIONS - p. 185 42. MANAGING CKD COMPLICATIONS - p. 195 43. STAGES IV AND V CKD - p. 214 44. END-STAGE KIDNEY DISEASE (ESKD) - p. 217 45. SPECIAL TOPICS IN CKD - p. 248 46. 5 Hypertension - p. 255 47. HYPERTENSION BACKGROUND AND DEFINITIONS - p. 255 48. EVALUATION OF HTN - p. 262 49. SECONDARY CAUSES OF HTN - p. 263 50. END-ORGAN DAMAGE OF HTN - p. 283 51. PHARMACOLOGIC THERAPY FOR HTN - p. 285 52. HYPERTENSIVE EMERGENCIES - p. 288 53. PREGNANCY AND HTN - p. 293 54. 6 Tubular, Interstitial, and Cystic Disorders - p. 301 55. RENAL TUBULAR DISORDERS AND FANCONI SYNDROME - p. 301 56. INTERSTITIAL/TUBULOINTERSTITIAL NEPHRITIS - p. 304 57. CHRONIC INTERSTITIAL NEPHRITIS - p. 311 58. RENAL CYSTIC DISEASES - p. 322 59. POLYCYSTIC KIDNEY DISEASES (PKDs) - p. 328 60. 7 Glomerular and Vascular Disorders - p. 349 61. GENERAL MANAGEMENT CONSIDERATIONS FOR GLOMERULAR/VASCULAR DISEASES (KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES [KDIGO] 2021) - p. 349 62. NEPHRITIC GLOMERULAR DISORDERS AND VASCULITIS/VASCULOPATHY - p. 354 63. RENAL AND SYSTEMIC VASCULITIDES - p. 360 64. LUPUS NEPHRITIS (LN) - p. 371 65. ANTI-GBM DISEASE (GOODPASTURE SYNDROME) - p. 379 66. GLOMERULAR INJURY ASSOCIATED WITH INFECTIONS - p. 382 67. NEPHROTIC/HEAVY PROTEINURIC GLOMERULAR DISORDERS - p. 391 68. PARAPROTEIN-RELATED DISORDERS - p. 406 69. ALPORT SYNDROME - p. 415 70. THROMBOTIC MICROANGIOPATHY / HEMOLYTIC-UREMIC SYNDROME - p. 420 71. DIABETIC KIDNEY DISEASE (DKD) - p. 430 72. SICKLE CELL DISEASE (SCD) - p. 436 73. VIRAL NEPHRITIDES - p. 441 74. FABRY DISEASE - p. 446 75. SCLERODERMA AND THE KIDNEYS - p. 448 76. 8 Transplant Immunobiology - p. 449 77. BACKGROUND - p. 449 78. HLA-TYPING TECHNIQUES - p. 453 79. MINOR HISTOCOMPATIBILITY ANTIGENS - p. 454 80. NON-HUMAN LEUKOCYTE ANTIGENS - p. 455 81. ALLORECOGNITION PATHWAYS: DIRECT, INDIRECT, AND SEMIDIRECT ALLORECOGNITION - p. 456 82. HLA ALLOSENSITIZATION - p. 457 83. TECHNIQUES FOR DETECTION OF ANTI-HLA ANTIBODIES: GENERAL CONCEPT - p. 457 84. DETERMINATION OF HLA SENSITIZATION - p. 458 85. VIRTUAL CROSSMATCH - p. 462 86. PHYSICAL CROSSMATCH - p. 463 87. IMMUNOLOGIC EVALUATION OF THE TRANSPLANT CANDIDATE - p. 465 88. 9 Kidney Transplantation - p. 467 89. EVALUATION OF THE POTENTIAL KIDNEY TRANSPLANT CANDIDATE - p. 467 90. LIVING DONOR EVALUATION - p. 473 91. KIDNEY ALLOCATION SYSTEM - p. 480 92. IMMUNOSUPPRESSIVE AGENTS - p. 482 93. ALLOGRAFT REJECTION: TYPES AND TREATMENT STRATEGIES - p. 491 94. KIDNEY ALLOGRAFT BIOPSY - p. 495 95. NONINVASIVE BIOMARKERS FOR EARLY DETECTION OF GRAFT INJURY AND REJECTION - p. 505 96. POSTTRANSPLANTATION INFECTIOUS COMPLICATIONS AND VACCINATIONS - p. 506 97. NONINFECTIOUS COMPLICATIONS AFTER KIDNEY TRANSPLANT - p. 521 98. POSTTRANSPLANTATION BONE AND MINERAL DISORDER - p. 534 99. POSTTRANSPLANTATION MALIGNANCY - p. 539 100. MALE AND FEMALE FERTILITY - p. 544 101. MULTIORGAN TRANSPLANTATION - p. 545 102. 10 Pharmacology - p. 549 103. PHARMACOKINETICS - p. 549 104. DRUG SELECTION AND DOSE ADJUSTMENT IN KIDNEY DISEASE - p. 554 105. NEPHROTOXICITY OF MEDICATIONS - p. 564 106. NEPHROTOXICITY OF ENVIRONMENTAL AND OCCUPATIONAL AGENTS - p. 572 107. SPECIFIC DRUG ADVERSE EFFECTS OF INTEREST TO THE NEPHROLOGIST - p. 573 108. IMMUNOSUPPRESSIVE THERAPY (see also Chapter 9: Kidney Transplantation) - p. 575 109. ANTICOAGULANTS, ANTIPLATELETS, THROMBOLYTICS, AND HEMOSTATICS - p. 577 110. DRUG INTERACTION/ADVERSE EFFECTS (OTHER THAN NEPHROTOXICITY) - p. 581 111. CORONAVIRUS DISEASE 2019 (COVID-19) DRUG THERAPY AND DRUG-DRUG INTERACTION/ADVERSE EFFECTS - p. 582 112. DIALYSIS AND OTHER TREATMENT OF POISONINGS - p. 583 113. COMMON POISONINGS THAT MAY REQUIRE EXTRACORPOREAL REMOVAL - p. 584 114. 11 Acute Kidney Injury/Intensive Care Unit (ICU) Nephrology - p. 589 115. ACUTE KIDNEY INJURY (AKI) - p. 589 116. ICU NEPHROLOGY - p. 619 117. HEMODYNAMIC MONITORING - p. 626 118. 12 Continuous Kidney Replacement Therapy - p. 631 119. BACKGROUND - p. 631 120. Appendix A: Facts, Formulas, and Protocols Beyond the ABIM Board Exam - p. 639 121. Appendix B: Supplemental Study Materials on Acid-Base Disorders - p. 677 122. Appendix C: Suggested Readings - p. 685 123. Practice Test - p. 698 124. Index - p. 699
No hay muestra disponible
No hay ficha técnica disponible
